Analysts expect ICU Medical, Inc. (NASDAQ:ICUI) to announce sales of $325.15 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for ICU Medical’s earnings. The lowest sales estimate is $322.10 million and the highest is $328.20 million. ICU Medical reported sales of $95.68 million during the same quarter last year, which indicates a positive year-over-year growth rate of 239.8%. The firm is scheduled to issue its next earnings results on Wednesday, March 7th.
According to Zacks, analysts expect that ICU Medical will report full year sales of $325.15 million for the current fiscal year, with estimates ranging from $1.22 billion to $1.25 billion. For the next financial year, analysts forecast that the business will post sales of $1.33 billion per share, with estimates ranging from $1.30 billion to $1.34 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover ICU Medical.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the consensus estimate of $0.77 by $0.35. ICU Medical had a net margin of 2.79% and a return on equity of 5.01%. The firm had revenue of $343.20 million during the quarter, compared to the consensus estimate of $328.56 million. During the same quarter in the prior year, the firm earned $1.35 EPS. ICU Medical’s revenue for the quarter was up 253.5% on a year-over-year basis.
Several equities analysts have issued reports on the stock. Gabelli reissued a “buy” rating on shares of ICU Medical in a research note on Friday, August 11th. BidaskClub cut shares of ICU Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Zacks Investment Research raised shares of ICU Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, KeyCorp assumed coverage on shares of ICU Medical in a research note on Tuesday, October 17th. They issued a “sector weight” rating on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $193.00.
In other ICU Medical news, CEO Vivek Jain sold 2,200 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $190.91, for a total value of $420,002.00. Following the transaction, the chief executive officer now directly owns 44,111 shares of the company’s stock, valued at approximately $8,421,231.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert S. Swinney sold 3,400 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $173.98, for a total transaction of $591,532.00. Following the completion of the transaction, the director now directly owns 20,893 shares in the company, valued at $3,634,964.14. The disclosure for this sale can be found here. Insiders sold a total of 120,247 shares of company stock worth $22,708,888 over the last three months. 13.60% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ICU Medical by 10.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 707 shares of the medical instruments supplier’s stock worth $122,000 after purchasing an additional 66 shares during the period. Riverhead Capital Management LLC grew its stake in shares of ICU Medical by 99.8% during the 2nd quarter. Riverhead Capital Management LLC now owns 999 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 499 shares during the period. Victory Capital Management Inc. grew its stake in shares of ICU Medical by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 1,050 shares of the medical instruments supplier’s stock worth $181,000 after purchasing an additional 157 shares during the period. Eagle Boston Investment Management Inc. acquired a new position in shares of ICU Medical during the 3rd quarter worth $200,000. Finally, Parametrica Management Ltd acquired a new position in shares of ICU Medical during the 2nd quarter worth $213,000. 78.16% of the stock is currently owned by institutional investors and hedge funds.
ICU Medical (NASDAQ:ICUI) traded up $18.95 during mid-day trading on Wednesday, reaching $205.05. 362,300 shares of the company traded hands, compared to its average volume of 127,310. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.66 and a current ratio of 4.78. The stock has a market cap of $4,510.00, a P/E ratio of 72.98 and a beta of 0.33. ICU Medical has a 1 year low of $127.00 and a 1 year high of $205.95.
WARNING: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/11/icu-medical-inc-icui-expected-to-post-quarterly-sales-of-325-15-million.html.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.